search
Back to results

Metabolically Normal and Metabolically Abnormal Obesity

Primary Purpose

Obesity, Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
overfeeding
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Obesity focused on measuring obesity, metabolism, cardiovascular metabolic syndrome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Obese subjects (BMI 30.0 - 39.9 kg/m2)
  • Sedentary subjects (exercise less than 1 hr/wk)

Exclusion Criteria:

  • Pregnant or lactating women
  • Michigan Alcohol Screening Test score ≥4
  • Active or previous history of liver disease
  • Active or previous history of diabetes
  • history of alcohol abuse, or currently consuming ≥20 g alcohol/day
  • Severe hypertriglyceridemia (>300 mg/dL)
  • Smoke tobacco
  • Take medication that might confound the study results

Sites / Locations

  • Washington University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Metabolically Normal

Metabolically Abnormal

Arm Description

Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy. Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.

Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy. Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.

Outcomes

Primary Outcome Measures

Change in Intrahepatic Triglyceride
Change in de novo lipogenesis
Change in VLDL kinetics
Change in hepatic insulin sensitivity
Change in skeletal muscle insulin sensitivity

Secondary Outcome Measures

Change in adipose tissue insulin sensitivity
Change in CD36 concentration in skeletal muscle
change in CD36 concentration in adipose tissue
Change in cell proliferation (growth) rates in the colon

Full Information

First Posted
August 12, 2010
Last Updated
June 29, 2017
Sponsor
Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01184170
Brief Title
Metabolically Normal and Metabolically Abnormal Obesity
Official Title
Metabolically Normal and Metabolically Abnormal Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to learn more about why some obese persons are resistant to developing obesity-related metabolic diseases (such as diabetes and cardiovascular disease), while others are prone to developing these conditions. We will do this by studying obese persons before and after a 5% body weight gain. Subjects will be asked to increase their current diet for a period of 8-12 weeks in order to increase their current body weight by 5%. Each will then be asked to maintain this weight increase for 3 weeks. We will monitor subjects throughout this time period with weekly medical evaluations. At the completion of the study, we will provide each subject with a 6-month weight loss program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Metabolic Syndrome
Keywords
obesity, metabolism, cardiovascular metabolic syndrome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metabolically Normal
Arm Type
Experimental
Arm Description
Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy. Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
Arm Title
Metabolically Abnormal
Arm Type
Experimental
Arm Description
Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy. Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
Intervention Type
Behavioral
Intervention Name(s)
overfeeding
Other Intervention Name(s)
directed weight gain
Intervention Description
Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
Primary Outcome Measure Information:
Title
Change in Intrahepatic Triglyceride
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in de novo lipogenesis
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in VLDL kinetics
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in hepatic insulin sensitivity
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in skeletal muscle insulin sensitivity
Time Frame
an average of three months, from baseline to 5% weight gain
Secondary Outcome Measure Information:
Title
Change in adipose tissue insulin sensitivity
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in CD36 concentration in skeletal muscle
Time Frame
an average of three months, from baseline to 5% weight gain
Title
change in CD36 concentration in adipose tissue
Time Frame
an average of three months, from baseline to 5% weight gain
Title
Change in cell proliferation (growth) rates in the colon
Time Frame
an average of three months, from baseline to 5% weight gain

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Obese subjects (BMI 30.0 - 39.9 kg/m2) Sedentary subjects (exercise less than 1 hr/wk) Exclusion Criteria: Pregnant or lactating women Michigan Alcohol Screening Test score ≥4 Active or previous history of liver disease Active or previous history of diabetes history of alcohol abuse, or currently consuming ≥20 g alcohol/day Severe hypertriglyceridemia (>300 mg/dL) Smoke tobacco Take medication that might confound the study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Klein, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31004409
Citation
Yoshino J, Patterson BW, Klein S. Adipose Tissue CTGF Expression is Associated with Adiposity and Insulin Resistance in Humans. Obesity (Silver Spring). 2019 Jun;27(6):957-962. doi: 10.1002/oby.22463. Epub 2019 Apr 19.
Results Reference
derived
PubMed Identifier
26376348
Citation
Fabbrini E, Tiemann Luecking C, Love-Gregory L, Okunade AL, Yoshino M, Fraterrigo G, Patterson BW, Klein S. Physiological Mechanisms of Weight Gain-Induced Steatosis in People With Obesity. Gastroenterology. 2016 Jan;150(1):79-81.e2. doi: 10.1053/j.gastro.2015.09.003. Epub 2015 Sep 12.
Results Reference
derived
PubMed Identifier
25555214
Citation
Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, Fraterrigo G, Okunade AL, Patterson BW, Klein S. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest. 2015 Feb;125(2):787-95. doi: 10.1172/JCI78425. Epub 2015 Jan 2.
Results Reference
derived

Learn more about this trial

Metabolically Normal and Metabolically Abnormal Obesity

We'll reach out to this number within 24 hrs